Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Suspended 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Primary Myelofibrosis 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Leukemia 1Glioblastoma 1

Interventions

Cyclophosphamide 346Cytarabine 282fludarabine phosphate 203Methotrexate 186Filgrastim 159Busulfan 148Etoposide 135Peripheral Blood Stem Cell Transplantation 134fludarabine 128Rituximab 119Radiotherapy 111Vincristine 102Cyclosporine 98Daunorubicin 96Antilymphocyte Serum 94Dexamethasone 91Tacrolimus 86Mycophenolic Acid 86Whole-Body Irradiation 81Melphalan 79Imatinib Mesylate 69Idarubicin 67Granulocyte Colony-Stimulating Factor 66Mercaptopurine 65Azacitidine 65Methylprednisolone 59Doxorubicin 58Prednisone 57Clofarabine 54sargramostim 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia × KB004 × Clear all
NCT01211691 2015-11-17

Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF)

Humanigen, Inc.

Phase 1/2 Suspended
120 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasms, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡